- Home
- PODD vs MRNA Comparison
PODD vs MRNA Comparison
Compare PODD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODD
- MRNA
- Stock Information
- Founded
- PODD 2000
- MRNA 2010
- Country
- PODD United States
- MRNA United States
- Employees
- PODD N/A
- MRNA N/A
- Industry
- PODD Medical/Dental Instruments
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PODD Health Care
- MRNA Health Care
- Exchange
- PODD Nasdaq
- MRNA Nasdaq
- Market Cap
- PODD 16.5B
- MRNA 16.0B
- IPO Year
- PODD 2007
- MRNA 2018
- Fundamental
- Price
- PODD $282.80
- MRNA $35.53
- Analyst Decision
- PODD Buy
- MRNA Hold
- Analyst Count
- PODD 16
- MRNA 20
- Target Price
- PODD $291.81
- MRNA $59.65
- AVG Volume (30 Days)
- PODD 598.2K
- MRNA 13.6M
- Earning Date
- PODD 02-20-2025
- MRNA 02-14-2025
- Dividend Yield
- PODD N/A
- MRNA N/A
- EPS Growth
- PODD 96.40
- MRNA N/A
- EPS
- PODD 5.78
- MRNA N/A
- Revenue
- PODD $2,071,600,000.00
- MRNA $3,236,000,000.00
- Revenue This Year
- PODD $23.56
- MRNA N/A
- Revenue Next Year
- PODD $18.07
- MRNA $21.39
- P/E Ratio
- PODD $48.93
- MRNA N/A
- Revenue Growth
- PODD 22.07
- MRNA N/A
- 52 Week Low
- PODD $160.19
- MRNA $29.25
- 52 Week High
- PODD $289.46
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- PODD 54.94
- MRNA 48.60
- Support Level
- PODD $270.00
- MRNA $32.78
- Resistance Level
- PODD $288.95
- MRNA $36.98
- Average True Range (ATR)
- PODD 6.83
- MRNA 2.50
- MACD
- PODD -0.31
- MRNA 0.30
- Stochastic Oscillator
- PODD 65.78
- MRNA 66.81
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.